Verastem Advances KRAS G12D Lung Cancer Trial with First Patient Dosing — Verastem, Inc.

Event summary

Verastem Oncology dosed the first patient in its TARGET-D 202 Phase 2 trial for VS-7375, targeting KRAS G12D-mutated advanced NSCLC.
The trial is designed to evaluate VS-7375 monotherapy at a daily dose of 900 mg in patients who have progressed after prior treatments.
This marks the second registration-directed Phase 2 trial for VS-7375, following the TARGET-D 201 pancreatic cancer study initiated last month.
VS-7375 has received Fast Track Designation from the FDA for treating KRAS G12D-mutated NSCLC.

The big picture

Verastem's advancement of the TARGET-D 202 trial underscores its strategic focus on developing targeted therapies for RAS/MAPK pathway-driven cancers. The company is positioning VS-7375 as a potential best-in-class treatment, aiming to address a significant unmet need in KRAS G12D-mutated NSCLC, where current therapies are limited and outcomes are poor. This trial initiation follows the recent dosing of the first patient in the TARGET-D 201 pancreatic cancer study, indicating Verastem's aggressive push to expand its clinical pipeline across multiple tumor types.

What we're watching

Clinical Progress: The pace at which Verastem can complete patient enrollment and generate efficacy data in the TARGET-D 202 trial will determine its path to potential FDA approval.
Competitive Positioning: Whether VS-7375 can differentiate itself from other KRAS G12D inhibitors in development, particularly given its dual ON/OFF inhibition mechanism.
Regulatory Strategy: How Verastem leverages the Fast Track Designation to accelerate the review process and potentially secure approval for VS-7375 in KRAS G12D-mutated NSCLC.